Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial
Figure 1
Schematic diagram of study design and vaccination schedule.
The CONSORT diagram indicates the number of subjects screened to complete enrollment of 31 subjects. Subjects were stratified as group 1 (primary immunization) versus group 2 (secondary immunization) and randomized to receive rAd5 vaccine by Biojector or needle and syringe. Group 1 included 8 subjects with adenovirus serotype 5 neutralizing antibody reciprocal titer ≤500 randomized equally into sub groups 1a and 1b.